Immuneering Announces FDA Clearance of IND Application for P

- Dosing of first patient in the Phase 1/2a clinical trial expected in early 2024 -

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , United States , Ben Zeskind , Gina Nugent , Brett Hall , Laurence Watts , Kiki Patel , Exchange Commission , Nugent Communications , Immuneering Corporation Nasdaq , Drug Administration , Immuneering Corporation , Gilmartin Group , Investigational New Drug , Chief Executive Officer , Chief Scientific Officer , Private Securities Litigation Reform Act , Quarterly Report , United States Securities , Region ,